Project Grant R21CA318322
Award Date 8/6/26
Completion Date 7/31/28
Dollars Obligated $421K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94107, USA
Similar Awards
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $640,466 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop covalent protein radiopharmaceuticals for targeted radionuclide therapy in cancer treatment. The project, funded through a Project Grant (R01CA309883), addresses a fundamental challenge in radiopharmaceutical design: balancing tumor uptake efficacy with safety by minimizing radiation exposure to normal...
- The National Cancer Institute awarded the University of California, San Diego $411,206 on May 14, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small molecule inhibitors of the proton-sensing receptor GPR68 for pancreatic ductal adenocarcinoma therapy. The research targets the acidic tumor microenvironment in pancreatic cancer, which drives tumor progression and immunosuppression. The work will develop and test GPR68-targeting pharmacological agents designed to block...
- The National Cancer Institute awarded $667,482 to the University of California, Davis on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop second-generation nanomedicine targeting treatment resistance in pancreatic ductal adenocarcinoma. The project develops an autophagy-inhibitor self-delivered nanodrug (AISN) containing a bisaminoquinoline derivative designed to overcome drug resistance driven by pancreatic cancer stem-like cells and drug-tolerant...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $575,178 on May 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop radiopharmaceuticals termed "restricted interaction peptides" (RIPs) targeting human kallikrein 2 for molecularly targeted radiotherapy of metastatic castration-resistant prostate cancer. The project tests whether RIPs—low molecular weight peptides internally cleaved by tumor...
- The National Cancer Institute awarded the Regents of the University of California, San Francisco $700,838 on April 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and optimize magnetic resonance multi-tasking abdominal imaging (MT-AI2) and advanced non-coplanar planning methods for functional avoidance stereotactic body radiation therapy (FA-SBRT) in primary and secondary liver tumors. The project aims to reduce radiation-induced liver disease (RILD)...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $636,345 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize the molecular mechanisms of PI3K activation in cancer using biochemical assays and cryo-electron microscopy imaging. The project focuses on phosphoinositide 3-kinase alpha (PI3KA), one of the most frequently mutated proteins in cancer. Researchers will elucidate how receptor tyrosine kinases and RAS...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $635,782 on August 12, 2026, under the Cancer Treatment Research program (CFDA 93.395) to establish a co-clinical imaging framework for defining noninvasive biomarkers of therapy-induced cardiotoxicity. The project combines hyperpolarized 13C MRI to quantify pyruvate dehydrogenase, lactate dehydrogenase, and alanine aminotransferase fluxes; 31P MR spectroscopic imaging to measure...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Rochester $624,494 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate combined stereotactic body radiotherapy and interleukin-12 messenger RNA nanotechnology as a treatment strategy for pancreatic ductal adenocarcinoma. The research targets T cell dynamics in the pancreatic cancer tumor microenvironment by combining localized stereotactic body...
- The National Cancer Institute awarded the Regents of the University of California, San Francisco $421,685 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop hyperpolarized 13C MRI as a biomarker for predicting immunotherapy response in cancer patients. The project addresses a clinical gap in immunotherapy monitoring: current imaging methods based on computed tomography and magnetic resonance imaging cannot reliably distinguish...
- The National Cancer Institute awarded University of Massachusetts Medical School $1.06 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer multi-targeted nanoparticle-based immunotherapy for pancreatic cancer. The funded work develops lipid-based nanoparticles (NPs) carrying RAS pathway inhibitors (trametinib, palbociclib, or RMC-7977) and STING/TLR4 innate immune agonists, designed to home specifically to tumor cells and dendritic cells within the...